Synonym
AX20017; AX-20017; AX 20017; PknG Inhibitor;
IUPAC/Chemical Name
2-(Cyclopropanecarbonylamino)-2,3,3a,4,5,6,7,7a-octahydro-1-benzothiophene-3-carboxamide
InChi Key
IEETZPYULYBOCV-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H20N2O2S/c14-11(16)10-8-3-1-2-4-9(8)18-13(10)15-12(17)7-5-6-7/h7-10,13H,1-6H2,(H2,14,16)(H,15,17)
SMILES Code
O=C(C1C(NC(C2CC2)=O)SC3C1CCCC3)N
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
268.37
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Baska F, Székely ER, Szántai-Kis C, Bánhegyi P, Hegymegi-Barakonyi B, Németh G, Breza N, Zsákai L, Greff Z, Pató J, Kéri G, Orfi L. [Development and study of structure-activity relationship of drugs against Mycobacterium tuberculosis]. Acta Pharm Hung. 2013;83(3):88-95. Hungarian. PubMed PMID: 24369587.
2: Santhi N, Aishwarya S. Insights from the molecular docking of withanolide derivatives to the target protein PknG from Mycobacterium tuberculosis. Bioinformation. 2011;7(1):1-4. Epub 2011 Aug 20. PubMed PMID: 21904430; PubMed Central PMCID: PMC3169209.
3: Székely R, Wáczek F, Szabadkai I, Németh G, Hegymegi-Barakonyi B, Eros D, Szokol B, Pató J, Hafenbradl D, Satchell J, Saint-Joanis B, Cole ST, Orfi L, Klebl BM, Kéri G. A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling. Immunol Lett. 2008 Mar 15;116(2):225-31. doi: 10.1016/j.imlet.2007.12.005. Epub 2008 Jan 8. PubMed PMID: 18258308.
4: Scherr N, Honnappa S, Kunz G, Mueller P, Jayachandran R, Winkler F, Pieters J, Steinmetz MO. Structural basis for the specific inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12151-6. Epub 2007 Jul 6. Erratum in: Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16388. PubMed PMID: 17616581; PubMed Central PMCID: PMC1924570.
5: Walburger A, Koul A, Ferrari G, Nguyen L, Prescianotto-Baschong C, Huygen K, Klebl B, Thompson C, Bacher G, Pieters J. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science. 2004 Jun 18;304(5678):1800-4. Epub 2004 May 20. PubMed PMID: 15155913.
